Fadi Haddad

Trials

Studies that name Fadi Haddad as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:15 UTC. Open this list on ClinicalTrials.gov

• Ph1/Ph2
  NCT07604233 · Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML

  M.D. Anderson Cancer Center · not yet recruiting · Myeloid Leukemia · principal investigator
• Ph2
  NCT07269470 · Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

  M.D. Anderson Cancer Center · recruiting · Chronic Myeloid Leukemia · principal investigator
• Ph2
  NCT06817720 · Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Chronic Myeloid Leukemia in Chronic Phase After Failing One Prior Therapy With a Second Generation Tyrosine Kinase Inhibitor or Asciminib

  M.D. Anderson Cancer Center · recruiting · Chronic Myeloid Leukemia · principal investigator
• N/A
  NCT04402814 · IgG/IgM Antibody Test in Patients Who Have Tested Negative or Positive for COVID-19 With the Standard Method of COVID19 Testing.

  Fadi Haddad, M.D. · unknown · SARS-CoV 2 · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 10:15 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.